Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients: Original Article

Nephrology

Volumn 15, Issue 1, 2010, Pages 27-32

  Jing, Sun ^a   Kezhou, Yu ^a   Hong, Zhang ^a   Qun, Wang ^a   Rong, Wang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Peritoneal dialysis; Peritoneal fibrosis; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AQUAPORIN 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRONECTIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77149135573     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01162.x     Document Type: Article

References (40)

1. Shao JC, Yorioka N, Nishida Y, Yamakido M. Effect of pH and glucose on cultured human peritoneal mesothelial cells. Scand. J. Urol. Nephrol. 1999 33 : 248 256.
2. Gandhi VC, Humayun HM, Ing TS et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch. Intern. Med. 1980 140 : 1201 1203.
3. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am. J. Kidney Dis. 1996 28 : 420 427.
4. Slingeneyer A, Mion C, Mourad G, Canaud B, Faller B, Béraud JJ. Progressive sclerosing peritonitis: A late and severe complication of maintenance peritoneal dialysis. Trans. Am. Soc. Artif Intern. Organs 1983 29 : 633 640.
5. Rottembourg J, Issad B, Langlois P et al. Loss of ultrafiltration and sclerosing encapsulating peritonitis during CAPD evaluation of the potential risk factors. Adv.CAPD 1985 1 : 109 117.
6. Witowski J, Ksiazek K, Jorres A. New insights into the biology of peritoneal mesothelial cells: The roles of epithelial-to-mesenchymal transition and cellular senescence. Nephron Exp. Nephrol. 2008 108 : e69 73.
7. Lee HB, Ha H. Mechanisms of epithelial-mesenchymal transition of peritoneal mesothelial cells during peritoneal dialysis. J. Korean Med. Sci. 2007 22 : 943 945.
8. Selgas R, Bajo A, Jiménez-Heffernan JA et al. Epithelial-to- mesenchymal transition of the mesothelial cell - its role in the response of the peritoneum to dialysis. Nephrol. Dial. Transplant. 2006 21 (Suppl 2 ii2 7.
9. Lai KN, Leung JC, Chan LY et al. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin. Exp. Immunol. 2004 138 : 466 475.
10. Ito H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int. 2004 65 : 1927 1936.
11. Margetts PJ, Bonniaud P, Liu L et al. Transient overexpression of TGF-1 induces epihelial mesenchymal transition in the rodent peritoneum. J. Am. Soc. Nephrol. 2005 16 : 425 436.
12. Senger DR, Brown LF, Claffey KP, Dvorak HF. Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis 1994 14 : 385 394.
13. Horowitz JR, Rivard A, van der Zee R et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol. 1997 17 : 2793 2800. (Pubitemid 28016023)
14. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989 246 : 1306 1309.
15. Imai H, Nakamoto H, Ishida Y et al. Renin-angiotensin system plays an important role in the regulation of water transport in the peritoneum. Adv. Perit. Dial. 2001 17 : 20 4.
16. Xie J, Wu K, Wang W, Li Y, Ren H, Chen N. Role of angiotensin II in peritoneal fibrosis and its related signal pathways (Abstract). J. Am. Soc. Nephrol. 2006 17 : 756A.
17. Noh H, Kim JS, Han KH et al. Oxidative stress during peritoneal dialysis: Implications in functional and structural changes in the membrane. Kidney Int. 2006 69 : 2022 2028.
18. Twardowski ZJ, Nolph K, Khanna R et al. Peritoneal equilibration test. Perit. Dial. Bull. 1987 7 : 138 147.
19. Mujais S, Nolph K, Gokal R et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000 20 (Suppl 4 S5 21.
20. Williams JD, Craig KJ, Topley N et al. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J. Am. Soc. Nephrol. 2002 13 : 470 479.
21. De Vriese AS, Mortier S, Lameire NH. Neoangiogenesis in the peritoneal membrane: Does it play a role in ultrafiltration failure? Nephrol. Dial. Transplant. 2001 16 : 2143 2145.
22. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit. Dial. Int. 2003 23 : 530 541.
23. Kalluri R, Sukhatme VP. Fibrosis and angiogenesis. Curr. Opin. Nephrol. Hypertens. 2000 9 : 413 418.
24. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N. Engl. J. Med. 2000 342 : 1350 1358.
25. Zarrinkalam KH, Stanley JM, Gray J et al. Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients. Kidney Int. 2003 64 : 331 338.
26. Offner FA, Feichtinger H, Stadlmann S et al. Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am. J. Pathol. 1996 148 : 1679 1688. (Pubitemid 26135907)
27. Aroeira LS, Aguilera A, Selgas R et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: Role of vascular endothelial growth factor. Am. J. Kidney Dis. 2005 46 : 938 948.
28. Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 2001 12 : 993 1000.
29. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol. Dial. Transplant. 1996 11 : 498 506.
30. Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int. 2002 61 : 570 578.
31. Hayakawa H. Study of peritoneal water transporter expression in rats. Jpn. J. Nephrol. 1996 38 : 535 544.
32. Carlsson O, Nielsen S, Zakaria ER, Rippe B. In vivo inhibition of transcellular water channels (aquaporin-1) during acute peritoneal dialysis in rats. Am. J. Physiol. (Heart Circ Physiol 40) 1996 271 : H2254 62.
33. Lai KN, Li FK, Lan HY et al. Expression of aquaporin-1 in human peritoneal mesothelial cells and its upregulation by glucose in vitro. J. Am. Soc. Nephrol. 2001 12 : 1036 1045.
34. Fang W, Oreopoulos DG, Bargman JM. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol. Dial. Transplant. 2008 23 : 3704 3710.
35. Kolesnyk I, Dekker FW, Noordzij M, le Cessie S, Struijk DG, Krediet RT. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit. Dial. Int. 2007 27 : 446 453.
36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 1993 329 : 1456 1462.
37. Lewis EJ, Hunsicker LG, Clarke WR et al. on behalf of the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001 345 : 851 860.
38. Miyazaki M, Yuzawa Y. The role of peritoneal fibrosis in encapsulating Peritoneal sclerosis. Perit. Dial. Int. 2005 25 : S48 56.
39. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am. J. Kidney Dis. 2004 43 : 1056 1064.
40. Duman S, Sen S, Duman C, Oreopoulos DG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int. J. Artif. Organs 2005 28 : 156 163.